What is the main therapeutic effect of filgotinib?

Filgotinib(Filgotinib) is a selective Janus kinase 1 (JAK1) inhibitor, mainly used to treat immune-mediated chronic inflammatory diseases, especially in the field of rheumatic immunity. The drug, originally developed by Galapagos, was developed to achieve a better balance between safety and efficacy, particularly by reducing widespread suppression of the immune system during long-term use.

Currently, filgotinib has been approved by the European Union for the treatment of patients with moderately to severely active rheumatoid arthritis (RA), especially those who have an inadequate response to or are intolerant to one or more traditional disease-modifying antirheumatic drugs (csDMARDs). Rheumatoid arthritis is an autoimmune disease characterized by chronic synovitis, joint destruction, and pain. By inhibiting the JAK1 signaling pathway, filgotinib regulates the abnormal expression of cytokines such as IL-6 and IFNγ, thereby inhibiting the immune inflammatory response, achieving the effects of relieving symptoms, reducing joint damage, and delaying disease progression.

In addition toRA, the potential efficacy of filgotinib in other immune-related diseases such as ulcerative colitis (UC), Crohn's disease (CD), and psoriatic arthritis (PsA) has also been widely studied. In the treatment of ulcerative colitis, filgotinib has shown potential to control intestinal mucosal inflammation, providing a new option for patients who are refractory to TNF-α inhibitors or other traditional treatments.

One of the greatest therapeutic advantages of filgotinib is its excellent oral bioavailability and selectivity. Compared with other JAK inhibitors, it is more selective for JAK1 and reduces non-specific inhibition of JAK2, JAK3 and other targets, thereby reducing the incidence of blood system-related side effects (such as anemia, neutropenia, etc.). In addition, its once-daily dosing frequency improves patient compliance and quality of life.

Reference materials:https://go.drugbank.com/drugs/DB14845